Literature DB >> 2745265

Twelve-hourly dosage schedule for oral and intravenous metronidazole.

P Earl1, P R Sisson, H R Ingham.   

Abstract

Paired samples of blood were examined from 48 patients undergoing major surgery who were receiving metronidazole at a 12-hourly dosage interval, as part of a regimen for prophylaxis or therapy. Twenty-five patients were given 400 mg metronidazole orally twice a day and 23 received 500 mg metronidazole iv twice daily. Assay of the samples demonstrated trough serum concentrations of metronidazole of 3-11 mg/l (mean 5.5 mg/l) and 2-15 mg/l (mean 6.7 mg/l) with the oral and intravenous routes, respectively. The corresponding peak serum concentrations were 10-26 mg/l (mean 17.4 mg/l) and 13-28 mg/l (mean 23.6 mg/l). The trough concentrations are well in excess of the MICs for the majority of obligate anaerobes and thus the 12-hourly regimen achieves and maintains therapeutic serum concentrations of metronidazole.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2745265     DOI: 10.1093/jac/23.4.619

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Disposition of intravenous metronidazole in Asian surgical patients.

Authors:  T Y Ti; H S Lee; Y M Khoo
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

2.  Sequential antibiotic therapy: Effective cost management and patient care.

Authors:  L A Mandell; M G Bergeron; M J Gribble; P J Jewesson; D E Low; T J Marrie; L E Nicolle
Journal:  Can J Infect Dis       Date:  1995-11

Review 3.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

5.  In vitro activities of metronidazole and its hydroxy metabolite against Bacteroides spp.

Authors:  S L Pendland; S C Piscitelli; P C Schreckenberger; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.